Nuvation Bio Inc. 8K

Nuvation Bio Inc. announced its Q2 2026 financial results and business update, showcasing strong IBTROZI revenue growth, expansion of its safusidenib glioma program, key regulatory and clinical milestones, and enhanced liquidity following a sizable convertible notes offering.

On August 6, 2026, Nuvation Bio Inc. reported its second quarter 2026 financial results and business update, highlighting $31.7 million in total revenue including $23.2 million in U.S. net product revenue from IBTROZI (taletrectinib), which has become the most prescribed ROS1 TKI for first-line and overall new ROS1+ NSCLC patient starts in 2026, while also emphasizing strong uptake among TKI-naive patients, positive updated long-term Phase 2 data and a significantly expanded clinical program for its IDH1-mutant glioma candidate safusidenib, the acquisition of Japan rights to safusidenib, progress on global regulatory and clinical milestones for IBTROZI, and bolstering of its capital structure through a $279.1 million public offering of 0.75% Convertible Senior Notes and an overall cash, cash equivalents, and marketable securities balance of $661.0 million as of June 30, 2026.

Filing Facts

CIK

1811063

Ticker

NUVB

Form

8K

Source Type

fda

Accession

0001193125-26-336751

Alert Tier

6